Parkin is an E3 ubiquitin ligase, a type of molecular enzyme that attaches ubiquitin molecules to selected proteins. Ubiquitin is often described as a cellular disposal tag, but that description is incomplete. Depending on the position and structure of the ubiquitin chain, the modification can influence protein stability, location, interactions, or signaling activity. Parkin is central to mitochondrial quality control. When mitochondria become damaged, the kinase PINK1 accumulates on their outer membranes and phosphorylates Parkin, helping activate the enzyme. Parkin then labels mitochondrial proteins with ubiquitin, attracting the autophagy machinery that removes the defective organelle. This process, called mitophagy, prevents damaged mitochondria from releasing toxic signals and helps preserve energy production. Although Parkin phosphorylation has been extensively studied, the researchers say the contribution of Parkin ubiquitination itself has remained unclear, particularly in cancer biology.

To identify relevant ubiquitination sites, the team used mass spectrometry, a highly sensitive analytical method that detects proteins and maps chemical modifications according to their molecular mass. The analysis identified lysine 27 as a site at which Parkin is ubiquitinated. The researchers then replaced this lysine with arginine, generating a mutant known as K27R. Because arginine cannot accept ubiquitin in the same manner as lysine, the substitution creates a ubiquitination-deficient version of Parkin. In cycloheximide chase experiments, which measure how quickly a protein disappears after new protein synthesis is blocked, the K27R mutant declined more rapidly than normal Parkin. This result indicated that ubiquitination at K27 helps protect Parkin from degradation and contributes to its stability. In practical terms, a cell may produce Parkin, but without the correct modification, the protein may not remain present long enough to perform its mitochondrial surveillance role.

The researchers also identified USP10 as a deubiquitinating enzyme that regulates Parkin. Deubiquitinating enzymes remove ubiquitin from proteins and can therefore reverse or reshape the effects of ubiquitination. USP10’s involvement adds another layer to the system: Parkin activity may depend not only on whether K27 is modified, but also on the balance between enzymes that add and remove ubiquitin. Such regulatory balance is common in signaling networks, where rapidly changing protein states allow cells to respond to stress. In cancer, however, disturbances in these controls can favor survival. If Parkin is destabilized or improperly regulated, damaged mitochondria may accumulate, energy production may be remodeled, and stress signals may be redirected toward pathways that support tumor growth.

The K27R mutation affected more than Parkin’s half-life. Experiments showed that the mutant was less capable of moving to mitochondria and interacted less efficiently with PINK1. This is a crucial finding because Parkin must be recruited to damaged mitochondria before it can initiate the ubiquitin-marking cascade required for mitophagy. The weakened interaction also suggested that Parkin phosphorylation was reduced. The relationship appeared to work in both directions. When the researchers used a phosphorylation-deficient Parkin mutant, S65A, the level of Parkin ubiquitination also fell. These observations point to molecular cross-talk: ubiquitination at K27 may help create a stable, activation-ready Parkin molecule, while phosphorylation at serine 65 may reinforce or promote Parkin ubiquitination. Rather than operating as separate switches, the two modifications appear to form an interconnected control circuit.

The consequences became visible at the level of mitochondria. Cells expressing the K27R mutant accumulated higher levels of mitochondrial membrane proteins, including markers associated with the outer and inner mitochondrial membranes. This pattern was consistent with impaired mitophagy, meaning that damaged or surplus mitochondria were not being efficiently cleared. Mitochondrial failure can produce more than an energy deficit. Mitochondria contain their own DNA, and when their membranes become compromised, mitochondrial DNA can escape into the cytoplasm. Because cytosolic DNA resembles a danger signal, it can activate cyclic GMP-AMP synthase, or cGAS. Activated cGAS generates a messenger molecule that stimulates STING, an adaptor protein positioned on intracellular membranes. The cGAS-STING pathway then triggers inflammatory and antiviral gene programs, including the production of interferon-related factors and chemokines such as CXCL10. The study links defective Parkin regulation to this mitochondrial DNA alarm system in cervical cancer cells.

Inflammation generated by cGAS-STING is biologically complex. In healthy tissue, it can help eliminate infected or damaged cells, but persistent activation may reshape the tumor environment and influence cancer-cell survival, immune interactions, and treatment responses. In the experiments, the Parkin mutant was associated with activation of cGAS-STING-related signaling, including increased expression of interferon-associated genes. The findings do not mean that every form of inflammation suppresses cancer or that cGAS-STING activation has a single outcome. Instead, they indicate that defective mitochondrial quality control can alter the signaling landscape within tumor cells. Parkin may therefore act as a connection point between organelle maintenance and innate immune signaling. The effect could be especially important in tumors that rely on metabolic flexibility, allowing them to tolerate mitochondrial damage while using stress responses to persist under challenging conditions.

Metabolic measurements revealed another major shift. Cells carrying the Parkin ubiquitination-deficient mutant showed reduced oxidative phosphorylation, the mitochondrial process that generates ATP through the electron transport chain, while intracellular glycolysis increased. Oxidative phosphorylation is efficient but depends on healthy mitochondria and an intact respiratory system. Glycolysis converts glucose into energy in the cell’s cytoplasm and can continue even when mitochondrial respiration is compromised, although it produces less ATP per molecule of glucose. Cancer cells frequently exploit this flexibility, increasing glucose consumption and lactate production to sustain growth in oxygen-limited or otherwise stressful environments. The researchers assessed these changes using oxygen consumption rate and extracellular acidification rate measurements, which provide functional estimates of mitochondrial respiration and glycolytic activity. The results suggest that loss of properly regulated Parkin pushes cervical cancer cells away from mitochondrial energy production and toward a glycolysis-dominant state.

This metabolic reprogramming was accompanied by more aggressive behavior in laboratory assays. The Parkin mutant promoted tumor spheroid formation, a three-dimensional culture model often used to examine self-renewal, cell survival, and tumor-initiating characteristics. In animal experiments, cells expressing the mutant also accelerated tumor growth. Together, the results support the idea that intact Parkin ubiquitination contributes to tumor suppression, while disruption of the K27-dependent regulatory mechanism weakens mitochondrial quality control and increases malignant potential. The authors propose that Parkin ubiquitination could eventually serve as a biomarker or therapeutic target in cervical cancer. However, the evidence currently comes from molecular experiments, cultured cancer cells, spheroids, and in vivo models rather than from clinical trials. It remains necessary to determine how frequently K27 ubiquitination is altered in patients, whether USP10 activity predicts treatment response, and whether manipulating this pathway can suppress tumors without damaging normal tissues that depend on mitophagy.

The study offers a broader lesson about cancer biology: protein modifications cannot always be understood in isolation. Parkin phosphorylation has long been recognized as a key event in mitophagy, but the new findings show that ubiquitination can influence the protein’s stability, mitochondrial recruitment, phosphorylation state, and downstream effects on immunity and metabolism. A single residue, K27, may therefore help coordinate several layers of cellular decision-making. The work also raises the possibility that therapies aimed at Parkin, USP10, or related enzymes could be combined with treatments targeting metabolism or cGAS-STING signaling. Such strategies would require careful validation, because mitochondrial stress and innate immune activation can have different effects depending on the tumor and its surrounding tissue. For now, the research identifies a previously hidden control mechanism linking Parkin modification to cervical cancer progression and provides a molecular explanation for how defective mitochondrial housekeeping may help tumors survive, adapt, and grow.

Subject of Research: Parkin ubiquitination, mitochondrial quality control, mitophagy, metabolism, and tumor suppression in cervical cancer

Article Title: Ubiquitination of parkin influences its tumor suppressive function in cervical cancer

Article References: Mai, Y., Hua, H., Liang, S. et al. “Ubiquitination of parkin influences its tumor suppressive function in cervical cancer.” Cellular and Molecular Life Sciences (2026).

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06362-3

Keywords: Parkin ubiquitination; Parkin phosphorylation; mitophagy; tumorigenesis; cervical cancer; USP10; cGAS-STING; mitochondrial DNA; oxidative phosphorylation; glycolysis

At the heart of cellular bioenergetics, mitochondrial fusion and fission must strike a delicate balance for optimal function. Fusion joins mitochondria, facilitating efficient ATP production through oxidative phosphorylation (OXPHOS) and controlling reactive oxygen species (ROS) levels. Conversely, fission fragments mitochondria, a process essential for cell division, apoptosis, and metabolic reprogramming. In normal cells, these opposing forces cooperate to maintain metabolic homeostasis. However, in cancer cells, and particularly in TNBC, this equilibrium shifts decisively toward excessive fission, fueling the malignant traits of unchecked proliferation, enhanced metastatic potential, and the maintenance of cancer stem cell-like properties.

Breast cancer exhibits profound metabolic heterogeneity, a feature most prominent in the notoriously treatment-resistant TNBC. While the historical Warburg effect posited glycolysis as the dominant energy source even in oxygen-rich environments, emerging data highlight the complexity of mitochondrial metabolism’s role in cancer biology. TNBC cells leverage fatty acid oxidation (FAO) and robust mitochondrial respiration to satisfy their heightened energetic and biosynthetic demands. Enzymes like fatty acid synthase (FASN) and ATP citrate lyase elevate de novo lipogenesis, supporting membrane biosynthesis and oncogenic signaling pathways necessary for rapid tumor expansion.

Interestingly, although primary breast tumors often rely heavily on glycolysis, metastatic lesions display increased tricarboxylic acid (TCA) cycle flux and enhanced ATP generation via OXPHOS, underscoring a metabolic plasticity that allows cancer cells to adapt to varied microenvironmental stresses such as hypoxia and nutrient deprivation. This metabolic flexibility confers survival advantages and contributes to chemotherapy resistance, making mitochondrial bioenergetics a central hub for therapeutic exploration.

Mitochondrial dynamics proteins emerge as critical modulators of these metabolic shifts. The fission machinery, principally mediated by dynamin-related protein 1 (Drp1) and its receptor Fis1, is frequently upregulated in TNBC. Drp1 overexpression correlates with poor clinical prognosis and is implicated in enhancing Notch1-driven chemoresistance pathways. By promoting mitochondrial fragmentation, fission supports cell cycle progression, sustains cancer stemness, and facilitates metastatic dissemination.

On the other hand, mitochondrial fusion proteins, including mitofusins (MFN1/2) and optic atrophy 1 (OPA1), bolster mitochondrial networking, facilitating OXPHOS and balancing ROS levels. MFN2’s interaction with pyruvate kinase M2 (PKM2) attenuates glycolytic flux, imposing a metabolic check that counters oncogenic drive. Experimental inhibition of OPA1 diminishes tumor aggressiveness, emphasizing the nuanced role of fusion in moderating cancer phenotypes and suggesting potential targets to restrain malignancy.

Mitophagy, the selective autophagic clearance of damaged mitochondria, further intricately modulates the tumor milieu. The PINK1/Parkin pathway governs mitophagy, facilitating mitochondrial quality control and influencing ROS generation. In breast tumors deficient in BRCA1, mitophagy disruption elevates mitochondrial ROS, triggering NLRP3 inflammasome activation, a pro-inflammatory axis that enhances metastatic potential. Conversely, therapeutic promotion of mitophagy—using natural compounds like polyphyllin I and silibinin—can induce apoptosis in TNBC, revealing mitophagy’s dualistic role as both a survival mechanism and a vulnerability.

Therapeutic endeavors targeting mitochondrial dynamics have gained traction with preclinical studies illustrating that inhibiting mitochondrial fission can thwart cancer progression. Agents such as Mdivi-1, a Drp1 inhibitor, and the P110 peptide have demonstrated efficacy in reducing metastasis and restoring sensitivity to chemotherapeutic agents. Conversely, strategies that promote mitochondrial fusion, by enhancing MFN2 activity, repress glycolytic metabolism and impede tumor growth, providing a complementary avenue for intervention.

Moreover, modulating mitophagy has emerged as an innovative therapeutic modality. Compounds including warangalone and kaempferol induce excessive mitophagy, leading to mitochondrial dysfunction and cancer cell death, while others like cepharanthine counteract pro-survival mitophagy pathways. These findings underscore the therapeutic potential of finely tuning mitochondrial quality control processes to disrupt breast cancer’s resilient metabolic networks.

Despite promising progress, several challenges temper the clinical translation of mitochondrial-targeted therapies. Intratumoral heterogeneity means mitochondrial adaptations differ significantly among tumor subtypes and stages, necessitating precision medicine approaches. Furthermore, cancer cells’ metabolic plasticity often renders them adept at circumventing single-target treatments, underscoring the need for combinatorial regimens.

The realization of mitochondrial biomarkers as reliable clinical tools also remains in its infancy. Quantifying Drp1 expression or monitoring mitochondrial functional states through non-invasive technologies is critical to stratifying patients and gauging therapy responses. Adding another layer of complexity, advanced drug delivery systems, such as nanoparticle carriers engineered to selectively target tumor mitochondria, are being developed to enhance therapeutic efficacy and minimize off-target effects.

Looking forward, integrating multi-omics approaches to interrogate mitochondrial metabolism alongside immune modulation offers a promising research trajectory. Understanding the crosstalk between metabolic reprogramming and the tumor immune landscape may unveil synergistic combination treatments. Additionally, experimental therapies involving mitochondrial transplantation are being explored to restore mitochondrial function or alter metabolic dependencies within cancer cells, potentially opening transformative avenues in oncology.

In summation, mitochondrial dynamics stand at a crossroads of cellular metabolism, survival, and malignancy in breast cancer metastasis. Their regulation of fission, fusion, and mitophagy orchestrates complex adaptations that fuel tumor aggressiveness and therapy resistance. As our molecular understanding deepens, exploiting these mitochondrial processes represents a compelling strategy to dismantle the metabolic versatility that underpins treatment-refractory breast cancers. While hurdles remain, the future of mitochondrial-directed therapeutics in precision oncology shines brightly, promising renewed hope for patients battling aggressive breast cancer subtypes.

Subject of Research: Mitochondrial dynamics and metabolism in breast cancer metastasis

Article Title: Mitochondrial Dynamics in Breast Cancer Metastasis: From Metabolic Drivers to Therapeutic Targets

News Publication Date: 30-Mar-2025

Web References: DOI 10.14218/OnA.2025.00001

Image Credits: Bhuban Ruidas